首页> 美国卫生研究院文献>BMC Cancer >Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
【2h】

Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor

机译:酪氨酸激酶抑制剂治疗转移性肾细胞癌患者CC-趋化因子受体7表达的预后价值

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundCC-chemokine receptor seven (CCR7), a G-protein coupled receptor normally facilitating immune cells lymphatic homing, has recently been identified on several cancer cells in promoting invasion and lymphatic specific metastasis by mimicking normal leukocytes. As tyrosine kinase inhibitors for metastatic renal cell carcinoma (mRCC) mostly emphasized on vascular inhibition, whether the CCR7 expressing tumor cells with potential lymphatic invasion function could have an impact on mRCC patient’s drug response and survival, was unknown.
机译:背景CC趋化因子受体七(CCR7),一种通常促进免疫细胞淋巴归巢的G蛋白偶联受体,最近在几种癌细胞上被鉴定出通过模仿正常白细胞来促进侵袭和淋巴特异性转移。由于转移性肾细胞癌(mRCC)的酪氨酸激酶抑制剂主要强调血管抑制作用,因此表达CCR7的具有潜在淋巴侵袭功能的肿瘤细胞是否会影响mRCC患者的药物反应和生存尚不清楚。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号